Treace Medical Concepts Statistics
Total Valuation
TMCI has a market cap or net worth of $710.80 million. The enterprise value is $641.68 million.
| Market Cap | 710.80M |
| Enterprise Value | 641.68M |
Important Dates
The next confirmed earnings date is Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TMCI has 61.76 million shares outstanding. The number of shares has increased by 10.09% in one year.
| Shares Outstanding | 61.76M |
| Shares Change (YoY) | +10.09% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 25.91% |
| Owned by Institutions (%) | 67.55% |
| Float | 44.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.72 |
| Forward PS | 3.07 |
| PB Ratio | 5.05 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.41, with a Debt / Equity ratio of 0.50.
| Current Ratio | 4.41 |
| Quick Ratio | 3.58 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.59 |
Financial Efficiency
Return on equity (ROE) is -34.00% and return on invested capital (ROIC) is -24.86%.
| Return on Equity (ROE) | -34.00% |
| Return on Assets (ROA) | -20.00% |
| Return on Capital (ROIC) | -24.86% |
| Revenue Per Employee | $362,632 |
| Profits Per Employee | -$95,983 |
| Employee Count | 516 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 1.45 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.54% in the last 52 weeks. The beta is 0.28, so TMCI's price volatility has been lower than the market average.
| Beta (1Y) | 0.28 |
| 52-Week Price Change | -55.54% |
| 50-Day Moving Average | 13.13 |
| 200-Day Moving Average | 13.73 |
| Relative Strength Index (RSI) | 37.04 |
| Average Volume (30 Days) | 413,204 |
Short Selling Information
The latest short interest is 2.64 million, so 4.28% of the outstanding shares have been sold short.
| Short Interest | 2.64M |
| Short Previous Month | 2.93M |
| Short % of Shares Out | 4.28% |
| Short % of Float | 5.97% |
| Short Ratio (days to cover) | 6.13 |
Income Statement
In the last 12 months, TMCI had revenue of $187.12 million and -$49.53 million in losses. Loss per share was -$0.81.
| Revenue | 187.12M |
| Gross Profit | 151.94M |
| Operating Income | -51.43M |
| Pretax Income | -49.53M |
| Net Income | -49.53M |
| EBITDA | -36.55M |
| EBIT | -44.36M |
| Loss Per Share | -$0.81 |
Balance Sheet
The company has $123.20 million in cash and $68.90 million in debt, giving a net cash position of $54.30 million or $0.88 per share.
| Cash & Cash Equivalents | 123.20M |
| Total Debt | 68.90M |
| Net Cash | 54.30M |
| Net Cash Per Share | $0.88 |
| Equity / Book Value | 137.94M |
| Book Value Per Share | 2.23 |
| Working Capital | 153.33M |
Cash Flow
In the last 12 months, operating cash flow was -$34.58 million and capital expenditures -$11.46 million, giving a free cash flow of -$46.03 million.
| Operating Cash Flow | -34.58M |
| Capital Expenditures | -11.46M |
| Free Cash Flow | -46.03M |
| FCF Per Share | -$0.76 |
Margins
Gross margin is 81.20%, with operating and profit margins of -27.48% and -26.47%.
| Gross Margin | 81.20% |
| Operating Margin | -27.48% |
| Pretax Margin | -26.47% |
| Profit Margin | -26.47% |
| EBITDA Margin | -19.53% |
| EBIT Margin | -23.71% |
| FCF Margin | -24.60% |
Dividends & Yields
TMCI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.09% |
| Shareholder Yield | -10.09% |
| Earnings Yield | -7.12% |
| FCF Yield | -6.61% |
Analyst Forecast
The average price target for TMCI is $19.58, which is 70.41% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.58 |
| Price Target Difference | 70.41% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 20.35% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TMCI has an Altman Z-Score of 3.81 and a Piotroski F-Score of 1.
| Altman Z-Score | 3.81 |
| Piotroski F-Score | 1 |